← FDA DRUG APPROVALS

FDA ANDA · ANDA077210

PIOGLITAZONE

Sponsor: TEVA PHARMS USA

APPLICATION
ANDA077210
TYPE
ANDA
ORIGINAL APPROVAL
2014-01-10
LATEST ACTION
2024-06-20
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

PIOGLITAZONE HYDROCHLORIDEPrescription
PIOGLITAZONE HYDROCHLORIDE EQ 45MG BASE · TABLET · ORAL
PIOGLITAZONE HYDROCHLORIDEPrescription
PIOGLITAZONE HYDROCHLORIDE EQ 15MG BASE · TABLET · ORAL
PIOGLITAZONE HYDROCHLORIDEPrescription
PIOGLITAZONE HYDROCHLORIDE EQ 30MG BASE · TABLET · ORAL

Approval history

2024-06-20Labeling · Supplement 11 · standardAP
2018-11-26Labeling · Supplement 2 · standardAP
2018-11-26Labeling · Supplement 3 · standardAP
2014-01-10Original — Other Important Information from FDA ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →